Pumitamig
Pumitamig is a bispecific antibody that targets both PD-L1 and VEGF-A. Pumitamig can be used for the study of solid tumors[1].
Product Specifications
Product Name Alternative
PM-8002; BNT-327
UNSPSC
12352203
Target
PD-1/PD-L1; VEGFR
Related Pathways
Immunology/Inflammation; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
99.6
Smiles
[Pumitamig]
Molecular Weight
(172.48 kDa)
References & Citations
[1]Lingying Wu, et al. Efficacy and safety of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with solid tumors: Clinical data from advanced cervical cancer and platinum-resistant recurrent ovarian cancer cohorts. Journal of Clinical Oncology. Volume 42, Number 16_suppl.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items